ToolGen Files Corrected Registration Statement for 70 Billion Won Rights Offering After Regulatory Demand, Dilution and Financial Risks Reaffirmed
ToolGen has submitted a corrected securities registration statement for its 70 billion won rights offering, addressing the Financial Supervisory Service's demand for correction. The terms remain unchanged: 777,000 new shares at 90,200 won per share, representing an 8.64% dilution.
As of end-Q1 2026, the company had only about 5.7 billion won in cash, accumulated deficit of 170.5 billion won, and persistent operating losses. Proceeds will be allocated 37.5% to patent litigation legal fees and 41.3% to R&D.
Largest shareholder Genexine plans to subscribe to only about 10% of its 96,602 allocated shares, reducing its stake from 12.43% to 11.54%. Retail investors hold 80.95% of shares, and the stock has been designated as a cautionary item 15 times in three years.
Financial soundness indicators show a debt ratio of 7.7% and current ratio of 1,093.6%, but these are inflated by asset revaluation. Operating cash flow remains negative. Failure to achieve 5 billion won in sales from fiscal year 2027 could trigger a managed stock designation.
[AI Summary]The corrected registration statement allows the capital increase to proceed, but high investment risks persist due to poor financial health, patent litigation uncertainty, and low largest shareholder participation. The 8.64% dilution is confirmed, and medium-term risks include potential additional funding needs and stricter listing requirements.
KOSDAQ Filing Information
[Correction of Description] Securities Registration Statement (Equity Securities)